LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy

Alex Blyth, Chief Executive Officer of LIfT BioSciences, commented: “This successful raise in the first close of our Series A marks a key step toward our plans to advance our IMANs into clinical trials. With the strong pre-clinical data that we continue to amass, we believe that our N-LIfT platform can make a real difference in cancer and other disease areas. We continue to progress discussions with pharma companies to secure potential licensing and partnership deals to that end. I would like to thank our investors for their ongoing support and look forward to providing further updates as we move towards clinical trials.”

Share:

More News

Valerie Vanhooren, Co-Founder and CEO of Ona Therapeutics, added, “ADCs have transformed cancer treatment; however, the technology has been applied to a limited number of tumor targets. These limitations restrict the number of patients who can benefit from treatments and highlight the critical need to identify new broadly expressed tumor

“Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, today announced that the Data Safety and Monitoring Board (DSMB) has completed its first

“Patients deserve more than the currently available treatment options. TAR-200 is a groundbreaking therapy for early-stage bladder cancer, designed to deliver a sustained local release of medication directly into the bladder—right where it is needed,” said Biljana Naumovic, U.S. President, Oncology, Solid Tumor, Johnson & Johnson Innovative Medicine. “This innovation

Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare, said, “Zurletrectinib has demonstrated outstanding efficacy and safety profile in adult, adolescent, and pediatric patients with tumors harboring NTRK fusion genes, bringing better treatment options for patients with solid tumors. The Company is expanding the scope of its solid tumor